- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00246259
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
November 15, 2013 updated by: Janssen-Ortho Inc., Canada
An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or hallucinations).
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This is an open-label (all people know identity of intervention), randomized (the study drug is assigned by chance), multicenter (conducted in more than 1 center), and exploratory study in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality) or schizoaffective disorder (mixed psychiatric disorder relating to complex psychotic state that has features of both schizophrenia and mood disorder).
Duration of this study will be 24 months.
Study assessment visits will be conducted at Screening, Baseline, Week 2, every 4 weeks till Week 22, at Week 28, every 12 weeks till Week 88 and at Week 104.
All eligible participants will receive either risperidone long acting injection 25 milligram (mg) intramuscularly (into the muscle) along with their current oral medication (atypical antipsychotic - risperidone, quetiapine, olanzapine) or only their current oral medication.
Efficacy will be evaluated primarily by Positive and Negative Syndromes Scale (PANSS), time to relapse and Social and Occupational Functioning Assessment Scale (SOFAS).
Participants's safety will be evaluated throughout the study mainly by Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating Scale (BARS), and Simpson Angus Scale (SAS).
Study Type
Interventional
Enrollment (Actual)
77
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Quebec, Canada
-
-
Alberta
-
Calgary, Alberta, Canada
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Victoria, British Columbia, Canada
-
-
Nova Scotia
-
Dartmouth, Nova Scotia, Canada
-
-
Ontario
-
Kingston, Ontario, Canada
-
London, Ontario, Canada
-
Markham, Ontario, Canada
-
Sudbury, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
Verdun, Quebec, Canada
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 30 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- In-patients or out-patients
- Primary Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) diagnosis of schizophrenia, schizophreniform disorder or schizoaffective disorder for no longer than 3 years after diagnosis and treatment of a psychotic illness
- Positive and Negative Syndrome Scale (PANSS) score of 60-120 at Visit 1 and 2
- Currently on monotherapy atypical antipsychotic treatment below local label guidelines or treatment naive
- Able to complete self-assessments in either English or French
Exclusion Criteria:
- Current primary Axis-1 diagnosis other than schizophrenia, schizophreniform disorder or schizoaffective disorder, according to DSM-IV
- Current drug or alcohol dependence
- Treatment with a depot antipsychotic within 3 months of study start
- Confirmed or suspected history of lack of tolerability, hypersensitivity or allergy to risperidone
- Risperidone non-responders (based on evidence of adequate trial of treatment)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Risperidone long-acting injection (LAI)
Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
An oral atypical antipsychotic will also be administered in the first 3 weeks following initiation of Risperidone LAI, and for a maximum of 3 weeks following a dose increase.
|
Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
|
Active Comparator: Oral Antipsychotic
Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
Participants will be switched to another oral therapy as per Investigator's discretion.
|
Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 104 or Last Reported Visit (LRV)
Time Frame: Baseline, Week 104 or LRV
|
The PANSS provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme).
The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210.
Higher scores indicate worsening.
|
Baseline, Week 104 or LRV
|
Time to Relapse
Time Frame: Week 10 (post-stability) up to Week 104 or LRV
|
Time to relapse was calculated from the start of the maintenance phase to date of relapse according to Csernansky: "Psychiatric hospitalization; increased level of psychiatric care from start of maintenance period and 25 percent increase in total PANSS score from first maintenance visit, or 10 points increase where PANSS at start of maintenance period was 40 or less; deliberate self-injury, suicidal or homicidal ideation; violent to others; property damage; or substantial clinical deterioration, defined as Clinical Global Impression of Change (CGI-C) score of 6 (much worse)".
|
Week 10 (post-stability) up to Week 104 or LRV
|
Change From Baseline in Social and Occupational Functioning Assessment Scale (SOFAS) at Week 104 or LRV
Time Frame: Baseline, Week 104 or LRV
|
The SOFAS focused exclusively on participants' level of social and occupational functioning.
The SOFAS is a 100 point single item scale that rates functioning of a participant.
The scale values range from 1=most impaired to 100=healthiest individual.
The scale also includes a rating point of 0=missing information.
|
Baseline, Week 104 or LRV
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Calgary Depression Symptom Scale (CDSS) Score at Week 104 or LRV
Time Frame: Baseline, Week 104 or LRV
|
Co-morbid depressive symptoms are evaluated by change in CDSS Score which was developed to assess symptoms of depression in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).
It consists of 9 items, each scored from 0 (absent) to 3 (severe).
The total score is a sum of the scores of each item and may range from 0 to 27.
Higher score more severe pathology.
Data presented here represents the change from baseline to endpoint.
|
Baseline, Week 104 or LRV
|
Change From Baseline in Young Mania Rating Scale (YMRS) at Week 104 or LRV
Time Frame: Baseline, Week 104 or LRV
|
Co-morbid symptoms of mania are evaluated by change in YMRS Score which is an 11-item scale to assess symptoms of mania, Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe).
The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe).
The YMRS total score ranges from 0 (the least) to 60 (the worst).
|
Baseline, Week 104 or LRV
|
Change From Baseline Hamilton Anxiety Scale (HAM-A) Total Score at Week 104 or LRV
Time Frame: Baseline, Week 104 or LRV
|
The HAM-A is a 14-item scale designed to measure anxiety in individuals.
Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented.
The answers range from 0 which signifies a complete lack of that symptom to 4, which indicates a very severe show of anxiety with that symptom.
Total score ranges from 0 to 56.
Lower score indicates less affected.
|
Baseline, Week 104 or LRV
|
Percentage of Participants With Relapse
Time Frame: Week 10 (post-stability) up to Week 104 or LRV
|
Relapse was defined according to Csernansky: "Psychiatric hospitalization; increased level of psychiatric care from start of maintenance period and 25 percent increase in total PANSS score from first maintenance visit, or 10 points increase where PANSS at start of maintenance period was 40 or less; deliberate self-injury, suicidal or homicidal ideation; violent to others; property damage; or substantial clinical deterioration, defined as CGI-C score of 6 (much worse)".
|
Week 10 (post-stability) up to Week 104 or LRV
|
Number of Participants With Cognitive Assessment Using Trail A
Time Frame: Week -2, 104 or LRV
|
Cognitive assessments were done using Trail test A which measured variety of functions, including motor speed, visual scanning, attention and visual motor integration.
Participants must connect numbered circles in a variety of orders.
|
Week -2, 104 or LRV
|
Number of Participants With Cognitive Assessments Using Trail B
Time Frame: Week -2, 104 or LRV
|
Cognitive assessments were done using Trail test B, which measured variety of functions, including motor speed, visual scanning, attention and visual motor integration.
In Trail B, 2 sets of circles contain numbers and letters, and the participant must connect them in alternating order.
Trail B is also a measure of executive functions as it requires planning and decision-making.
|
Week -2, 104 or LRV
|
Total Words Score Over Time
Time Frame: Baseline, Week 104 or LRV
|
Controlled Word Association Test (COWAT) was used to assess verbal fluency.
Participants are given 3 different letters of the alphabet and asked to say as many words beginning with each letter within a controlled time.
Participants are then asked to identify as many words as possible in 3 different categories (animals, fruits and vegetables) within a specified period of time.
The total score is a sum of all three categories scores.
The total score ranges from 0-90, the higher the score the higher the verbal fluency.
|
Baseline, Week 104 or LRV
|
Change From Baseline in Drug Attitude Inventory (DAI-10) Score at Week 104 or LRV
Time Frame: Up to Week 104 or LRV
|
The DAI, a 10-item scale to assess how the attitude of schizophrenia participants toward their medications may affect compliance.
Respondents indicate 'true' or 'false' for each item.
An overall calculated score ranged from -10 to 10, where a positive score indicated a positive subjective response (compliant), a negative score indicated non-compliance.
Change: score at observation minus score at baseline.
|
Up to Week 104 or LRV
|
Change From Baseline in Standardized Mental Component Scale Score in Short Form 36 (SF-36) at Week 104 or LRV
Time Frame: Up to Week 104 or LRV
|
The SF-36 is a survey of participant health.
It calculates two standardized scales: the standardized mental component scale and the standardized physical component scale.
The standardized scales are calculated as weighted sums of the 8 scores, which are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.
Each item is scored on a 0-100 range; and standardized mental component scale score is calculated as weighted average of individual item scores on a 0-100 range, where 100 signify highest level of functioning.
The change from baseline in mental component scale score was reported.
|
Up to Week 104 or LRV
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Barnes Akathisia Rating Scale (BARS) Global Clinical Assessment
Time Frame: Baseline, Week 104 or LRV
|
The BARS evaluates akathisia (feeling of restlessness) associated with the use of antipsychotic medications, including an objective and a subjective component plus a global impression.
Components are rated on a scale of 0 (normal or absence of restlessness)-3 (intense restlessness) and 0 (absent)-5 (severe akathisia) for the global clinical assessment.
Number of participants in each global clinical assessment scale are reported.
|
Baseline, Week 104 or LRV
|
Simpson Angus Scale (SAS)
Time Frame: Baseline, Week 104 or LRV
|
The SAS is a 10-item scale used to measure the symptoms of parkinsonism (slow movements) or parkinsonian side-effects related to the use of antipsychotic medications.
The 10 items are rated on a 5-point scale (0=complete absence, 4=extreme presence) after a brief neurological examination and observation of the participants' gait (slow, shuffling walk).
Total score is sum of individual item scores (range 0 to 40); higher score indicates more affected.
|
Baseline, Week 104 or LRV
|
Abnormal Involuntary Movement Scale (AIMS)
Time Frame: Baseline, Week 104 or LRV
|
The AIMS is a 12-item scale to provide a numeric measure to the observed abnormal movements in different parts of the body.
Information is collected after a brief neurological examination and is scored on a 5-point scale (0=none, 4=severe).
Ten items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in three main anatomic areas (orofacial area, extremities, and trunk).
Two items are yes/no questions regarding dental status.
Total scores range from 0 to 42 with higher values indicating more severity.
|
Baseline, Week 104 or LRV
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2004
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
October 28, 2005
First Submitted That Met QC Criteria
October 28, 2005
First Posted (Estimate)
October 30, 2005
Study Record Updates
Last Update Posted (Estimate)
December 11, 2013
Last Update Submitted That Met QC Criteria
November 15, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Disease
- Psychotic Disorders
- Mental Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Risperidone
- Antipsychotic Agents
Other Study ID Numbers
- CR005959
- RISSCH4056
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychotic Disorders
-
Medical College of WisconsinCompletedSchizophrenia | Affective Disorders | Psychotic Disorder | Psychotic Mood Disorder
-
Søren Dinesen ØstergaardCompletedAffective Disorders, PsychoticDenmark
-
Instituto de Investigación Hospital Universitario...CompletedSchizophrenia and Disorders With Psychotic Feature | Psychotic EpisodeSpain
-
University of MinnesotaUniversity of California, San FranciscoCompletedPsychotic Disorders | Schizophrenia | Schizoaffective Disorder | Cognitive Impairment | Psychosis | Treatment | Psychotic Depression | Psychotic Episode | Active Control | Psychotic Mood DisordersUnited States
-
VA Office of Research and DevelopmentNot yet recruitingMI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMIHomelessness | Schizophrenia Spectrum Disorders | Psychotic Mood Disorders | Psychotic Affective Disorders | Ill-Housed PersonsUnited States
-
Instituto de Investigación Hospital Universitario...Carlos III Health Institute; European Regional Development FundCompletedSchizophrenia and Disorders With Psychotic Features | Psychotic EpisodeSpain
-
Centre hospitalier de Ville-Evrard, FranceRecruiting
-
University Hospital, CaenRecruiting
-
University of California, San DiegoActive, not recruitingSchizophrenia | Schizoaffective Disorder | Mood Disorder, PsychoticUnited States
-
Boston Medical CenterNational Institute of Mental Health (NIMH); Beth Israel Deaconess Medical CenterCompletedPsychotic Disorders | Psychosis | Psychotic EpisodeUnited States
Clinical Trials on Risperidone long-acting injection (LAI)
-
Janssen-Cilag S.p.A.CompletedSchizophrenia | Schizoaffective Disorder
-
Janssen-Ortho Inc., CanadaTerminatedSchizophreniaCanada, United Kingdom, Australia, Ireland
-
Northwestern UniversityOrtho-McNeil Janssen Scientific Affairs, LLCCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Janssen Cilag N.V./S.A.Completed
-
Intra-Cellular Therapies, Inc.CompletedSchizophreniaUnited States
-
Hospital Authority, Hong KongJanssen Pharmaceutica N.V., BelgiumUnknownPsychotic Disorders | Schizophrenia | Schizophrenia, Paranoid | Schizophrenia, Catatonic | Schizophrenia, DisorganizedChina
-
Mayo ClinicCompletedCirrhosis | Portal Hypertension | Esophageal Varices
-
Koneksa HealthCompleted
-
Janssen Pharmaceutica N.V., BelgiumCompletedBipolar DisorderChina, Taiwan, Colombia, India, Malaysia, Russian Federation, South Africa, Greece, Peru, Germany, Mexico, Lebanon, Indonesia, Philippines, Jordan
-
National Heart, Lung, and Blood Institute (NHLBI)Childhood Asthma Research and Education NetworkCompletedLung Diseases | Asthma